On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician’s scale says they moved less. The KINECT-PRO findings showed INGREZZA easing the daily burden of tardive dyskinesia in ways a rating scale alone never captures. The timing matters, because the data lands just weeks after a quarter that showed the rest of the business accelerating too. Together, the two releases sketch a company leaning harder into both clinical depth and commercial breadth at the same time.
A Drug Proving Its Worth Twice Over
The KINECT-PRO Phase 4 study followed 59 tardive dyskinesia patients on daily INGREZZA for 24 weeks, and 52 made it to that final visit. Among the 45 patients included in the efficacy analysis, about 58% hit the threshold for symptomatic remission on clinician-rated movement severity. What stands out is that the benefit did not depend on how bad things were at the start. Patients with only mild TD movements still improved meaningfully, and those gains showed up fast, exceeding the clinically meaningful threshold on movement severity by Week 4 and on patient-reported impact by Week 8. Safety held to the drug’s known profile, with nothing new flagged.
That clinical proof arrives alongside a business that is compounding. Neurocrine’s July 30 second-quarter report showed total revenue up 39% year over year to $959 million, with INGREZZA sales climbing 15% to $716 million on record new prescriptions. Management raised full-year INGREZZA guidance to $2.825 billion to $2.875 billion. Two younger drugs, CRENESSITY and the newly acquired VYKAT XR, added $184 million and $54 million respectively, giving the company two more legs to stand on beyond its original blockbuster.
The Bill Coming Due For Growth
Growth this broad rarely comes free. Neurocrine’s cash and marketable securities fell from roughly $2.5 billion at the end of 2025 to about $482 million by June 30, largely because the company paid $53.00 a share in cash to acquire Soleno Therapeutics, a $2.9 billion deal that closed in May. It backstopped the depleted balance sheet with a new $1.0 billion revolving credit facility, a sign the company wanted a cushion after spending down its reserves. Operating costs are climbing too. Second-quarter R&D rose to $327 million from $244 million a year earlier as the osavampator and direclidine Phase 3 programs advance toward 2027 readouts, while SG&A jumped to $440 million from $286 million as the sales force expanded and took on VYKAT XR.
The Soleno deal also loaded roughly $2.2 billion of intangible assets onto the balance sheet, which will now amortize over 16 years and weigh on GAAP earnings for well over a decade. And for all the diversification talk, INGREZZA still supplied about three-quarters of Neurocrine’s quarterly revenue, so the company’s fortunes remain tied tightly to one drug’s continued growth and to how tardive dyskinesia treatment evolves from here.
Where The Smart Money Stands
Hedge fund ownership slipped from 53 funds in the prior quarter to 45 in the most recent one, a pullback even as the underlying business posted 39% revenue growth. Short interest sits at 6.46% of float, enough to signal a real bear camp but far from a crowded trade. The stock trades at a forward P/E of 14.88 as of September 17, a modest multiple for a company raising guidance and expanding its pipeline. That gap suggests that the market is still digesting how much the Soleno spending and cash drawdown should weigh against the growth numbers.
The Two Stories Investors Must Reconcile
Neurocrine is simultaneously proving out its flagship drug on a deeper level and stretching its balance sheet to build what comes next. The KINECT-PRO data gives prescribers a stronger case for INGREZZA across a wider range of patients, reinforcing the moat around the company’s biggest revenue source. But the depleted cash position, the new credit line, and the still-heavy reliance on one drug are the kind of numbers that keep a bear case alive even during a growth quarter.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
